CDXS Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of -116.82%. Codexis, Inc.'s return on equity of -112.54% beat Agenus, Inc.'s return on equity of --.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 551.82%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Codexis, Inc. has higher upside potential than Agenus, Inc., analysts believe Codexis, Inc. is more attractive than Agenus, Inc..

Codexis, Inc. has a beta of 2.493, which suggesting that the stock is 149.337% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Codexis, Inc.'s net income of -$19.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 1.62x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Beam Therapeutics, Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of -1162.38%. Codexis, Inc.'s return on equity of -112.54% beat Beam Therapeutics, Inc.'s return on equity of -7.83%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 551.82%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $49.93 which suggests that it could grow by 75.45%. Given that Codexis, Inc. has higher upside potential than Beam Therapeutics, Inc., analysts believe Codexis, Inc. is more attractive than Beam Therapeutics, Inc..

Codexis, Inc. has a beta of 2.493, which suggesting that the stock is 149.337% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.118, suggesting its more volatile than the S&P 500 by 111.789%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are smaller than Beam Therapeutics, Inc. quarterly revenues of $114.1M. Codexis, Inc.'s net income of -$19.6M is lower than Beam Therapeutics, Inc.'s net income of $244.3M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 1.62x versus 20.24x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Incyte Corp. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of 19.86%. Codexis, Inc.'s return on equity of -112.54% beat Incyte Corp.'s return on equity of 30.48%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 551.82%. On the other hand Incyte Corp. has an analysts' consensus of $107.09 which suggests that it could grow by 5.75%. Given that Codexis, Inc. has higher upside potential than Incyte Corp., analysts believe Codexis, Inc. is more attractive than Incyte Corp..

Codexis, Inc. has a beta of 2.493, which suggesting that the stock is 149.337% more volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.840, suggesting its less volatile than the S&P 500 by 16.012%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are smaller than Incyte Corp. quarterly revenues of $1.5B. Codexis, Inc.'s net income of -$19.6M is lower than Incyte Corp.'s net income of $299.3M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 15.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 1.62x versus 3.96x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of -77256.06%. Codexis, Inc.'s return on equity of -112.54% beat Viridian Therapeutics, Inc.'s return on equity of -53.74%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 551.82%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.76 which suggests that it could grow by 41.95%. Given that Codexis, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Codexis, Inc. is more attractive than Viridian Therapeutics, Inc..

Codexis, Inc. has a beta of 2.493, which suggesting that the stock is 149.337% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.176%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are larger than Viridian Therapeutics, Inc. quarterly revenues of $132K. Codexis, Inc.'s net income of -$19.6M is higher than Viridian Therapeutics, Inc.'s net income of -$102M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 1.62x versus 35.15x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.